1 |
Boussios S, Mikropoulos C, Samartzis E, et al. Wise management of ovarian cancer: on the cutting edge [J]. J Pers Med, 2020, 10(2):41.
|
2 |
José-Enériz S, Gimenez-Camino, Agirre, et al. HDAC inhibitors in acute myeloid leukemia[J]. Cancers, 2019, 11(11):1794.
|
3 |
黄晴, 汤春晖. PCI-24781抑制上皮性卵巢癌SKOV-3细胞Wnt/β-catenin信号通路的研究[J]. 检验医学与临床, 2017, 20(v.36): 101-104.
|
4 |
Helland, Popa M, Bischof K, et al. The HDACi panobinostat shows growth inhibition both In vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer [J]. Plos One, 2016, 11(6): e0158208.
|
5 |
Kulka LAM, Fangmann PV, Panfilova D, et al. Impact of HDAC inhibitors on protein quality control systems: consequences for precision medicine in malignant disease [J]. Fron Cell Dev Biol, 2020, 8:425.
|
6 |
Kostova I, Mandal R, Becker S, et al. The role of caspase-8 in the tumor microenvironment of ovarian cancer [J]. Cancer Metastasis Rev, 2021, 40(1): 303-318.
|
7 |
Mirzaei S, Hushmandi K, Zabolian A, et al. Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: afocus on molecular pathways and possible therapeutic strategies [J]. Molecules (Basel, Switzerland), 2021, 26(8): 2382.
|
8 |
Hussain A, Dar MS, Bano N, et al. Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells [J]. Cancer Chemother Pharmacol, 2019, 84(3): 551-559.
|
9 |
Amit S, Anupam B, Abhay P. Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy [J]. Nutrients, 2018, 10(6): 731.
|
10 |
Najafi SMAA. Thecanonical Wnt signaling (Wnt/β-Catenin pathway): apotential target for cancer prevention and therapy [J]. Iran Biomed J, 2020, 24(5): 269-280.
|
11 |
Guergana T, Brigitte S. The double dealing of Cyclin D1 [J]. Cell Cycle, 2020, 19(2): 163-178.
|
12 |
Kaiser K, Gyllborg D, Procházka J, et al. WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis [J]. Nat Commun, 2019, 10(1): 1498.
|
13 |
Prasad CP, Manchanda M, Mohapatra P, et al. WNT5A as a therapeutic target in breast cancer [J]. Cancer Metastasis Rev, 2018, 37(4): 767-778.
|
14 |
Jin P, Yi S, Yu G. The role of abnormal methylation of Wnt5a gene promoter regions in human epithelial ovarian cancer: aclinical and experimental study [J]. Anal Cell Pathol (Amst), 2018, 2018: 6567081.
|
15 |
Abedini A, Zamberlam G, Lapointe E, et al. WNT5a is required for normal ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppressing canonical WNT signaling [J]. Faseb J, 2016, 30(4): 1534-1547.
|